iSpecimen Statistics
Total Valuation
iSpecimen has a market cap or net worth of $2.32 million. The enterprise value is $1.76 million.
Important Dates
The next estimated earnings date is Wednesday, March 12, 2025, before market open.
| Earnings Date | Mar 12, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
iSpecimen has 962,637 shares outstanding. The number of shares has increased by 20.33% in one year.
| Current Share Class | 962,637 |
| Shares Outstanding | 962,637 |
| Shares Change (YoY) | +20.33% |
| Shares Change (QoQ) | +21.18% |
| Owned by Insiders (%) | 11.60% |
| Owned by Institutions (%) | 7.59% |
| Float | 850,994 |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.13 |
| Forward PS | 0.78 |
| PB Ratio | 0.42 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.17 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.74, with a Debt / Equity ratio of 0.25.
| Current Ratio | 0.74 |
| Quick Ratio | 0.70 |
| Debt / Equity | 0.25 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -41.43 |
Financial Efficiency
Return on equity (ROE) is -109.34% and return on invested capital (ROIC) is -64.74%.
| Return on Equity (ROE) | -109.34% |
| Return on Assets (ROA) | -44.26% |
| Return on Capital (ROIC) | -64.74% |
| Revenue Per Employee | $196,051 |
| Profits Per Employee | -$179,697 |
| Employee Count | 53 |
| Asset Turnover | 0.75 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -74.67% in the last 52 weeks. The beta is 1.68, so iSpecimen's price volatility has been higher than the market average.
| Beta (5Y) | 1.68 |
| 52-Week Price Change | -74.67% |
| 50-Day Moving Average | 3.58 |
| 200-Day Moving Average | 5.05 |
| Relative Strength Index (RSI) | 35.24 |
| Average Volume (20 Days) | 1,179,567 |
Short Selling Information
The latest short interest is 71,667, so 7.44% of the outstanding shares have been sold short.
| Short Interest | 71,667 |
| Short Previous Month | 95,320 |
| Short % of Shares Out | 7.44% |
| Short % of Float | 8.42% |
| Short Ratio (days to cover) | 0.18 |
Income Statement
In the last 12 months, iSpecimen had revenue of $10.39 million and -$9.52 million in losses. Loss per share was -$17.63.
| Revenue | 10.39M |
| Gross Profit | 4.98M |
| Operating Income | -9.76M |
| Pretax Income | -10.20M |
| Net Income | -9.52M |
| EBITDA | -9.50M |
| EBIT | -9.76M |
| Loss Per Share | -$17.63 |
Full Income StatementBalance Sheet
The company has $1.75 million in cash and $1.19 million in debt, giving a net cash position of $563,479 or $0.59 per share.
| Cash & Cash Equivalents | 1.75M |
| Total Debt | 1.19M |
| Net Cash | 563,479 |
| Net Cash Per Share | $0.59 |
| Equity (Book Value) | 4.71M |
| Book Value Per Share | 5.68 |
| Working Capital | -1.61M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$4.35 million and capital expenditures -$48,681, giving a free cash flow of -$4.39 million.
| Operating Cash Flow | -4.35M |
| Capital Expenditures | -48,681 |
| Free Cash Flow | -4.39M |
| FCF Per Share | -$4.57 |
Full Cash Flow StatementMargins
Gross margin is 47.98%, with operating and profit margins of -93.92% and -91.66%.
| Gross Margin | 47.98% |
| Operating Margin | -93.92% |
| Pretax Margin | -91.66% |
| Profit Margin | -91.66% |
| EBITDA Margin | -91.47% |
| EBIT Margin | -93.92% |
| FCF Margin | n/a |